



ASX Announcement

26 April 2022

Atomo expands executive team

SYDNEY, Australia, 26 April 2022 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce the expansion and strengthening of its executive commercial team and a change in the COO role to better support renewed international commercial focus and operations activity, the role now being headquartered in Sydney. Key elements include:

- Based in San Diego, California, Jim McMenemy joins Atomo as Head of Business Development and Partnerships, the Americas
- Based in the UK, Anna Tucker joins Atomo as Head of Business Development and Partnerships, Europe, Middle East and Africa (EMEA)
- Based in Sydney, Chandra Sukumar assumes the role of COO, building on her experience running product development and OEM product management with the company. UK based Mark Smith is departing as Atomo's COO and transitioning to a consulting role during a transition period

Bringing onboard experienced commercial resources supports Atomo's strategic focus on establishing a new US business entity and expanding its commercial activity in high value developed markets, as well as reflecting a significantly changed diagnostic landscape post pandemic and the growing opportunity for and acceptance of rapid point-of-care (POC) and at-home testing.

Summary:

Jim McMenemy has over 30 years of experience in the global POC diagnostics market having had roles with companies such as Becton Dickinson, Quidel Corp, ACON Laboratories, Inverness Medical, AGEN Biomedical, Samsung Diagnostics and Henry Schein Animal Health. Jim has held leadership roles in areas of Marketing, Sales, Business Development and General Management in global human and veterinary POC diagnostics markets for these organisations. He has extensive experience in the successful development and commercialisation of numerous custom private label and company branded rapid diagnostic Lateral Flow and Molecular tests, including a number of US FDA approved professional use and OTC self-test products, targeting US and global Physician/Veterinarian and At-home Diagnostic Markets.

Anna Tucker brings to Atomo a proven track record of developing businesses across the Life Sciences sector, with more than 25 years' experience working in sales, distribution management and field marketing globally. As Director, Distributor Sales, EMEA at Congenica, Anna was responsible for driving revenue growth through the identification, selection and ongoing management of a network of distributors and expanding the commercial footprint of Congenica's diagnostic software and services business across EMEA. In her previous role as European Business Development Manager for Artel, Inc., Anna was responsible for building brand awareness in an untapped European market through direct activity and development of



distributor sales as well as the creation of a European-focused marketing strategy. Anna has previously held positions covering sales and marketing with a number of healthcare and technology companies globally. She brings to Atomo a wealth of experience in building and leading commercial teams and distributors and has a proven track record delivering results to her companies and their partners.

The promotion of Chandra Sukumar into the role of COO enables operational leadership to be based at Atomo's global headquarter based in Sydney. It also leverages her successful leadership directing Atomo's development programs for key platform programs such as Elion and our new integrated swab device (Blackburn), as well as her management of both technical and product support for Atomo's OEM customers, which is key as Atomo expands its market presence.

Chandra joined Atomo as Director of Programs in 2017, bringing with her more than 25 years of experience in the medical device industry. Chandra has extensive experience in the development of medical devices from conception to commercialisation, and prior to joining Atomo, was at ResMed for 14 years where she served in a number of leadership roles including supply chain management, global manufacturing, and APAC marketing.

For more information, please contact:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com